Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
10(55.6%)
Phase 2
4(22.2%)
Phase 3
4(22.2%)
18Total
Phase 1(10)
Phase 2(4)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT07570186Phase 1Not Yet Recruiting

Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants

Role: lead

NCT05257993Phase 1Recruiting

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Role: lead

NCT07370818Phase 2Not Yet Recruiting

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Role: lead

NCT07364422Phase 1Not Yet Recruiting

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Role: lead

NCT07265466Phase 1Recruiting

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Role: lead

NCT07181538Phase 1Completed

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

Role: lead

NCT07160790Phase 3Not Yet Recruiting

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

Role: lead

NCT06502743Phase 2Recruiting

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

Role: collaborator

NCT06439563Phase 3Recruiting

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Role: lead

NCT05475184Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Role: lead

NCT05443984Phase 3Completed

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Role: lead

NCT05448001Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Role: lead

NCT05712681Phase 1Completed

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Role: lead

NCT05814809Phase 1Completed

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Role: lead

NCT04282954Phase 2Completed

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Role: lead

NCT05181124Phase 1Completed

Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

Role: lead

NCT04335604Phase 1Completed

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Role: lead

NCT05194046Phase 1Completed

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Role: lead

All 18 trials loaded